Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 10/2005

01-10-2005 | Abstracts

5th ISoP Annual Meeting ‘Pharmacovigilance — A Global Concern: East Meets West’

Manila, Philippines 17–19 October, 2005

Published in: Drug Safety | Issue 10/2005

Login to get access

Excerpt

ISoP aims to promote the use of all types of information and methodologies in providing optimal drug treatment for patients. The Society is not only for clinical pharmacologists, the pharmaceutical industry, epidemiologists and regulators, but also for practising clinicians and other health professionals who are interested in discovering better ways to treat patients more safely with medicines. …
Literature
1.
Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005 Mar 17; 352(11): 1071–80PubMedCrossRef
2.
Benchou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs-II. J Clin Epidemiol 1993; 46: 1331–6CrossRef
3.
Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992; 27: 538PubMed
4.
Barne J, Aggarwal AM. Spontaneous reporting of ADRs associated with herbal medicines: a cross-sectional survey of national pharmacovigilance centres [abstract]. ISoP 2004. Drug Saf 2004; 27(12): 917
5.
Barnes J. An examination of the role of the pharmacist in the safe, effective and appropriate use of complementary medicines [PhD thesis]. London: University of London, 2001
6.
Wingfield J, Walmsley J, Norman C. What do Boots pharmacists know about yellow card reporting of adverse drug reactions? Pharm J 2002; 269: 109–10
7.
Cox AR, Marriott JF, Wilson KA, et al. Adverse drug reaction teaching in UK undergraduate medical and pharmacy programmes. J Clin Pharm Ther 2004; 29: 31–5PubMedCrossRef
8.
Ferner RE, Langford NJ, Anton C, et al. Random and systematic medication errors in routine clinical practice: a multicentre study of infusions, using acetylcysteine as an example. Br J Clin Pharmacol 2001 Nov; 52 (5): 573–7
9.
Jordan SD, Poole CJ, Archer VR, et al. A retrospective evaluation of the feasibility of intrapatient dose escalation as appropriate methodology for dose-ranging studies for combination cytotoxic regimens. Cancer Chemother Pharmacol 2003 Aug; 52(2): 113–8PubMedCrossRef
10.
New Civil Code (NCC) of the Philippines, Article 2187
11.
12.
Metadata
Title
5th ISoP Annual Meeting ‘Pharmacovigilance — A Global Concern: East Meets West’
Manila, Philippines 17–19 October, 2005
Publication date
01-10-2005
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 10/2005
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200528100-00009

Other articles of this Issue 10/2005

Drug Safety 10/2005 Go to the issue

Original Research Article

Fatal Venous Thromboembolism Associated with Different Combined Oral Contraceptives

Review Article

The Incidence of Prescribing Errors in Hospital Inpatients

Leading Article

Impact Analysis of Signals Detected from Spontaneous Adverse Drug Reaction Reporting Data

Leading Article

Clarification of Terminology in Drug Safety

Current Opinion

Data Mining in Pharmacovigilance

Original Research Article

Testing and Implementing Signal Impact Analysis in a Regulatory Setting